Vaccination coverage results in persons aged 1–29 years for Phase I of the first phase of the MenAfriVac introduction campaign presented by administrative coverage and Lot Quality Assurance (LQA) analysis, Filingue, Niger, October 2010.

Using mathematical models to evaluate and inform immunisation strategies with MenAfriVac in the African meningitis belt

Karachaliou Prasinou, Andromachi

April 2019

The countries of the African meningitis belt suffer from frequent epidemics due to meningococcal men...

MenC vaccination status among control individuals before and after public MenC vaccination, according to age group and MenC vaccine provider.

Cristiane Wanderley Cardoso (721406)
Guilherme Sousa Ribeiro (721407)
Mitermayer Galvão Reis (721408)
Brendan Flannery (352939)
Joice Neves Reis (721409)

April 2015

a Periods of MenC conjugate vaccine campaigns: February-December 2010 for <5 years old...

Efficacy and Effectiveness of the Meningococcal Conjugate Group A Vaccine MenAfriVac® in Preventing Recurrent Meningitis Epidemics in Sub-Saharan Africa

Simonetta Viviani

April 2022

For more than a century, epidemic meningococcal disease mainly caused by serogroup A Neisseria menin...

Vaccination coverage results in persons aged 1–29 years for the second phase of the MenAfriVac introduction by administrative methods and Clustered Lot Quality Assurance Sampling (CLQAS) survey, Niamey and Tillabéri, Niger, December 2010.

Sung Hye Kim (334729)
Lorenzo Pezzoli (334731)
Harouna Yacouba (334732)
Tiekoura Coulibaly (334733)
Mamoudou H. Djingarey (334734)
William A. Perea (334735)
Thomas F. Wierzba (111421)

February 2013

Vaccination coverage results in persons aged 1–29 years for the second phase of the MenAfriVac in...

MenAfriVac vaccination coverage in persons aged 1–29 years for the two phases presented by administrative coverage and coverage survey results, Niger, October–December 2010.

Sung Hye Kim (334729)
Lorenzo Pezzoli (334731)
Harouna Yacouba (334732)
Tiekoura Coulibaly (334733)
Mamoudou H. Djingarey (334734)
William A. Perea (334735)
Thomas F. Wierzba (111421)

February 2013

MenAfriVac vaccination coverage in persons aged 1–29 years for the two phases presented by admini...

Vaccination coverage per age group.

Leonoor Wijnans (408746)
Jeanne Dieleman (408747)
Bettie Voordouw (408748)
Miriam Sturkenboom (408749)

April 2013

Vaccination coverage per age group for seasonal influenza vaccination and first and second doses ...

Vaccination coverage for ≥2 doses of PCV10 among the <5 years old per year during the pre-intervention period, transition period and post-intervention period, 2009–2016.

Lukas Richter (6195785)
Daniela Schmid (701900)
Elisabeth Eva Kanitz (368265)
Ines Zwazl (6195788)
Eva Pöllabauer (6195791)
Joanna Jasinska (317677)
Heinz Burgmann (131783)
Michael Kundi (727003)
Ursula Wiedermann (314076)

January 2019

Vaccination coverage for ≥2 doses of PCV10 among the <5 years old per year during the pre-interventi...

Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010.

Sung Hye Kim
Lorenzo Pezzoli
Harouna Yacouba
Tiekoura Coulibaly
Mamoudou H Djingarey
William A Perea
Thomas F Wierzba

MenAfriVac is a new conjugate vaccine against Neisseria meningitidis serogroup A developed for the A...

Reasons for non-vaccination in the individuals reportedly not vaccinated during Phase I (n = 70) and Phase II (n = 53) of the MenAfriVac introduction campaign, Niamey and Tillabéri, Niger, September–December 2010.

Sung Hye Kim (334729)
Lorenzo Pezzoli (334731)
Harouna Yacouba (334732)
Tiekoura Coulibaly (334733)
Mamoudou H. Djingarey (334734)
William A. Perea (334735)
Thomas F. Wierzba (111421)

February 2013

Reasons for non-vaccination in the individuals reportedly not vaccinated during Phase I (n = 70) ...

Vaccination coverage by age in the areas targeted for vaccination in 2014.

Louis Albert Massing (5181083)
Soumah Aboubakar (5181080)
Alexandre Blake (3837595)
Anne-Laure Page (247439)
Sandra Cohuet (33744)
Adalbert Ngandwe (5181056)
Eric Mukomena Sompwe (168581)
Romain Ramazani (5181065)
Marcela Allheimen (5181068)
Philippe Levaillant (5181077)
Pauline Lechevalier (793890)
Marie Kashimi (5181059)
Axelle de la Motte (5181086)
Arielle Calmejane (5181062)
Malika Bouhenia (4803903)
Ernest Dabire (5181074)
Didier Bompangue (263679)
Benoit Kebela (5181071)
Klaudia Porten (262678)
Francisco Luquero (4369771)

May 2018

Vaccination coverage by age in the areas targeted for vaccination in 2014.</p

Weighted vaccination coverage estimates for the democratic republic of the Congo demographic and health survey respondents 12–59 months of age by survey year.

Vivian H. Alfonso (6733922)
Anna Bratcher (6733925)
Hayley Ashbaugh (6733928)
Reena Doshi (6733931)
Adva Gadoth (6733934)
Nicole Hoff (6733937)
Patrick Mukadi (5293796)
Angie Ghanem (6733940)
Alvan Cheng (6733943)
Sue Gerber (6733946)
Guillaume Ngoie Mwamba (6733949)
Jean Jacques Muyembe Tamfum (6733952)
Emile Okitolonda Wemakoy (6733955)
Anne W. Rimoin (131501)

May 2019

Weighted vaccination coverage estimates for the democratic republic of the Congo demographic and hea...

Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt.

Karachaliou, Andromachi
Conlan, Andrew
Preziosi, Marie-Pierre
Trotter, Caroline

November 2015

BACKGROUND: The introduction of MenAfriVac in campaigns targeting people aged 1-29 years across the ...

National level immunization coverage estimates, most recent births 12–23 months prior to survey to women 15–44 years.

Natalie Carvalho (49823)
Naveen Thacker (642558)
Subodh S. Gupta (642559)
Joshua A. Salomon (118304)

October 2014

*A fully vaccinated child was defined as a child who had received one dose of BCG vaccine, 3 dose...

a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged

Ray Borrow
George Carlone
Simonetta Viviani

August 2016

Background. Mass vaccination campaigns of the population aged 1–29 years with 1 dose of group A meni...

Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt

Andromachi Karachaliou
Andrew J. K. Conlan
Marie-pierre Preziosi
Caroline L. Trotter

August 2016

Background. The introduction of MenAfriVac in campaigns targeting people aged 1–29 years across the ...

Using mathematical models to evaluate and inform immunisation strategies with MenAfriVac in the African meningitis belt

Karachaliou Prasinou, Andromachi

April 2019

The countries of the African meningitis belt suffer from frequent epidemics due to meningococcal men...

MenC vaccination status among control individuals before and after public MenC vaccination, according to age group and MenC vaccine provider.

Cristiane Wanderley Cardoso (721406)
Guilherme Sousa Ribeiro (721407)
Mitermayer Galvão Reis (721408)
Brendan Flannery (352939)
Joice Neves Reis (721409)

April 2015

a Periods of MenC conjugate vaccine campaigns: February-December 2010 for <5 years old...

Efficacy and Effectiveness of the Meningococcal Conjugate Group A Vaccine MenAfriVac® in Preventing Recurrent Meningitis Epidemics in Sub-Saharan Africa

Simonetta Viviani

April 2022

For more than a century, epidemic meningococcal disease mainly caused by serogroup A Neisseria menin...

Vaccination coverage results in persons aged 1–29 years for the second phase of the MenAfriVac introduction by administrative methods and Clustered Lot Quality Assurance Sampling (CLQAS) survey, Niamey and Tillabéri, Niger, December 2010.

Sung Hye Kim (334729)
Lorenzo Pezzoli (334731)
Harouna Yacouba (334732)
Tiekoura Coulibaly (334733)
Mamoudou H. Djingarey (334734)
William A. Perea (334735)
Thomas F. Wierzba (111421)

February 2013

Vaccination coverage results in persons aged 1–29 years for the second phase of the MenAfriVac in...

MenAfriVac vaccination coverage in persons aged 1–29 years for the two phases presented by administrative coverage and coverage survey results, Niger, October–December 2010.

Sung Hye Kim (334729)
Lorenzo Pezzoli (334731)
Harouna Yacouba (334732)
Tiekoura Coulibaly (334733)
Mamoudou H. Djingarey (334734)
William A. Perea (334735)
Thomas F. Wierzba (111421)

February 2013

MenAfriVac vaccination coverage in persons aged 1–29 years for the two phases presented by admini...

Vaccination coverage per age group.

Leonoor Wijnans (408746)
Jeanne Dieleman (408747)
Bettie Voordouw (408748)
Miriam Sturkenboom (408749)

April 2013

Vaccination coverage per age group for seasonal influenza vaccination and first and second doses ...

Vaccination coverage for ≥2 doses of PCV10 among the <5 years old per year during the pre-intervention period, transition period and post-intervention period, 2009–2016.

Lukas Richter (6195785)
Daniela Schmid (701900)
Elisabeth Eva Kanitz (368265)
Ines Zwazl (6195788)
Eva Pöllabauer (6195791)
Joanna Jasinska (317677)
Heinz Burgmann (131783)
Michael Kundi (727003)
Ursula Wiedermann (314076)

January 2019

Vaccination coverage for ≥2 doses of PCV10 among the <5 years old per year during the pre-interventi...

Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010.

Sung Hye Kim
Lorenzo Pezzoli
Harouna Yacouba
Tiekoura Coulibaly
Mamoudou H Djingarey
William A Perea
Thomas F Wierzba

MenAfriVac is a new conjugate vaccine against Neisseria meningitidis serogroup A developed for the A...

Reasons for non-vaccination in the individuals reportedly not vaccinated during Phase I (n = 70) and Phase II (n = 53) of the MenAfriVac introduction campaign, Niamey and Tillabéri, Niger, September–December 2010.

Sung Hye Kim (334729)
Lorenzo Pezzoli (334731)
Harouna Yacouba (334732)
Tiekoura Coulibaly (334733)
Mamoudou H. Djingarey (334734)
William A. Perea (334735)
Thomas F. Wierzba (111421)

February 2013

Reasons for non-vaccination in the individuals reportedly not vaccinated during Phase I (n = 70) ...

Vaccination coverage by age in the areas targeted for vaccination in 2014.

Louis Albert Massing (5181083)
Soumah Aboubakar (5181080)
Alexandre Blake (3837595)
Anne-Laure Page (247439)
Sandra Cohuet (33744)
Adalbert Ngandwe (5181056)
Eric Mukomena Sompwe (168581)
Romain Ramazani (5181065)
Marcela Allheimen (5181068)
Philippe Levaillant (5181077)
Pauline Lechevalier (793890)
Marie Kashimi (5181059)
Axelle de la Motte (5181086)
Arielle Calmejane (5181062)
Malika Bouhenia (4803903)
Ernest Dabire (5181074)
Didier Bompangue (263679)
Benoit Kebela (5181071)
Klaudia Porten (262678)
Francisco Luquero (4369771)

May 2018

Vaccination coverage by age in the areas targeted for vaccination in 2014.</p

Weighted vaccination coverage estimates for the democratic republic of the Congo demographic and health survey respondents 12–59 months of age by survey year.

Vivian H. Alfonso (6733922)
Anna Bratcher (6733925)
Hayley Ashbaugh (6733928)
Reena Doshi (6733931)
Adva Gadoth (6733934)
Nicole Hoff (6733937)
Patrick Mukadi (5293796)
Angie Ghanem (6733940)
Alvan Cheng (6733943)
Sue Gerber (6733946)
Guillaume Ngoie Mwamba (6733949)
Jean Jacques Muyembe Tamfum (6733952)
Emile Okitolonda Wemakoy (6733955)
Anne W. Rimoin (131501)

May 2019

Weighted vaccination coverage estimates for the democratic republic of the Congo demographic and hea...

Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt.

Karachaliou, Andromachi
Conlan, Andrew
Preziosi, Marie-Pierre
Trotter, Caroline

November 2015

BACKGROUND: The introduction of MenAfriVac in campaigns targeting people aged 1-29 years across the ...

National level immunization coverage estimates, most recent births 12–23 months prior to survey to women 15–44 years.

Natalie Carvalho (49823)
Naveen Thacker (642558)
Subodh S. Gupta (642559)
Joshua A. Salomon (118304)

October 2014

*A fully vaccinated child was defined as a child who had received one dose of BCG vaccine, 3 dose...

a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged

Ray Borrow
George Carlone
Simonetta Viviani

August 2016

Background. Mass vaccination campaigns of the population aged 1–29 years with 1 dose of group A meni...

Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt

Andromachi Karachaliou
Andrew J. K. Conlan
Marie-pierre Preziosi
Caroline L. Trotter

August 2016

Background. The introduction of MenAfriVac in campaigns targeting people aged 1–29 years across the ...

Using mathematical models to evaluate and inform immunisation strategies with MenAfriVac in the African meningitis belt

Karachaliou Prasinou, Andromachi

April 2019

The countries of the African meningitis belt suffer from frequent epidemics due to meningococcal men...

MenC vaccination status among control individuals before and after public MenC vaccination, according to age group and MenC vaccine provider.

Cristiane Wanderley Cardoso (721406)
Guilherme Sousa Ribeiro (721407)
Mitermayer Galvão Reis (721408)
Brendan Flannery (352939)
Joice Neves Reis (721409)

April 2015

a Periods of MenC conjugate vaccine campaigns: February-December 2010 for <5 years old...

Efficacy and Effectiveness of the Meningococcal Conjugate Group A Vaccine MenAfriVac® in Preventing Recurrent Meningitis Epidemics in Sub-Saharan Africa

Simonetta Viviani

April 2022

For more than a century, epidemic meningococcal disease mainly caused by serogroup A Neisseria menin...

Vaccination coverage results in persons aged 1–29 years for Phase I of the first phase of the MenAfriVac introduction campaign presented by administrative coverage and Lot Quality Assurance (LQA) analysis, Filingue, Niger, October 2010.

Abstract

Extracted data

Vaccination coverage results in persons aged 1–29 years for Phase I of the first phase of the MenAfriVac introduction campaign presented by administrative coverage and Lot Quality Assurance (LQA) analysis, Filingue, Niger, October 2010.

Abstract

Extracted data

Related items

Related items